Get to know our clinical trials
Trial with durvalumab (MEDI4736) odurvalumab and tremelimumab, in patients with advanced stage intrahepatic bile duct cancer (BTC) who were to receive SIRT Y-90 therapy as standard treatment.
THE AIM OF THIS CLINICAL TRIAL IS THEREFORE TO COMBINE FOR THE FIRST TIME TWO TREATMENT METHODS (IMMUNOTHERAPY WITH CONCOMITANT SIRT TREATMENT) TO TEST WHETHER IN THE FUTURE IT COULD BE USEFUL TO TREAT BILE DUCT CARCINOMA WITH IMMUNOTHERAPY AND CONCOMITANT SIRT TREATMENT.
Technical Summary
- A PHASE II STUDY OF IMMUNOTHERAPY WITH DURVALUMAB (MEDI4736) OR DURVALUMAB AND TREMELIMUMAB, BOTH COMBINED WITH SIRT Y-90 THERAPY IN PATIENTS WITH ADVANCED-STAGE INTRAHEPATIC BILE DUCT CANCER (BTC) WHO WERE TO RECEIVE SIRT Y-90 THERAPY AS STANDARD TREATMENT. IMMUNOTHERAPY
- Code EudraCT: 2018-004778-81
- Protocol number: IMMUWHY
- Promoter: Institut für Klinische Krebsforschung IKF GmbH
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.